Literature DB >> 19855234

Biochemical testing for neuroendocrine tumors.

Aaron I Vinik1, Maria P Silva, Eugene A Woltering, Gene Woltering, Vay Liang W Go, Richard Warner, Martyn Caplin.   

Abstract

In this review, we focus on the use of biochemical markers for the diagnosis of neuroendocrine tumors and exclusion of conditions that masquerade as neuroendocrine tumors. In addition, we outline the use of biochemical markers for follow-up, response to intervention, and determination of prognosis. Previous publications have focused only on markers specific to certain tumor types, but the uniqueness of this chapter is that it presents a new approach ranging from biochemical markers that relate to symptoms to the use of markers that facilitate decision making with regard to optimizing the choices of therapy from the complex arrays of intervention, The sequence of presentation in this chapter is first to provide the usual view, that is, biochemical markers of each tumor type and thereafter the diagnosis of the underlying condition or exclusion thereof and finally the algorithm for their use from the clinical presentation to the suspected diagnosis and the biochemical markers to monitor progression and therapeutic choice. There is also a specific description of the properties of the most important biochemical markers and 2 complications, bone metastasis and carcinoid heart disease, from the biochemical point of view.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855234     DOI: 10.1097/MPA.0b013e3181bc0e77

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  34 in total

1.  Pancreastatin predicts survival in neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2014-04-22       Impact factor: 5.344

2.  A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Kristen M Stashek; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

3.  Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.

Authors:  Michelle Kang Kim; Fei Ye; Daguang Wang; Miao Cui; Stephen C Ward; Richard R P Warner; Sasan Roayaie; Michail Shafir; Myron Schwartz; David Zhang; Steven Itzkowitz
Journal:  Pancreas       Date:  2016-04       Impact factor: 3.327

4.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 5.  The use of biomarkers in neuroendocrine tumours.

Authors:  Mohid Shakil Khan; Martyn E Caplin
Journal:  Frontline Gastroenterol       Date:  2013-03-21

Review 6.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

7.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 8.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

9.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

Review 10.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.